Navigation Links
Antipsychotic Iloperidone Results Show Favorable Akathisia Profile

tients taking antipsychotics discontinued treatment within 18 months, primarily because of insufficient efficacy and tolerability issues.

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc., headquartered in Rockville, Maryland, is a biopharmaceutical company working to advance the science of personalized medicine to improve the lives of patients with schizophrenia. The company has three product candidates in clinical development. Vanda's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia and has completed its Phase III program. Vanda's second product candidate, VEC- 162, is a compound for the treatment of sleep and mood disorders which is currently in Phase III for insomnia. Vanda's third product candidate, VSF-173, is a compound for the treatment of excessive sleepiness and is ready for a Phase II clinical trial. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

Note Regarding Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Words such as, but not limited to, "suggest," "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "may," "would," "should," and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, a failure of iloperidone or Vanda's other product candidates to be demonstrably safe and effective, a failure to obtain regulatory approval for iloperidone or the company's other product candidates, a lack of acceptance
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. New Data Show Early Non-Response to Antipsychotic Treatment May Be Strong Predictor of Subsequent Non-Response for People with Schizophrenia
2. Vanda Pharmaceuticals to Present Data on Iloperidone at the 2007 American Psychiatric Association Annual Meeting
3. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
4. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
5. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
8. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
9. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis

Post Your Comments:
(Date:11/7/2009)... Fla., Nov. 7 Patients reported C1...ective therapy in treating acute swelling attacks ...enetic disorder, according to data presented today...amp; Immunology (ACAAI) Annual Meeting. The result...ducted in parallel with the ongoing, prospective, ...
(Date:11/6/2009)...h., Nov. 6 SCOLR Pharma,...ts for the three and nine months ended September 3... President and CEO, said, "We continue to advance ...ofen formulation. Several potential partners have ... and external resources as they evaluate the poten...
(Date:11/6/2009)...ov. 6 Recession in domes... sales for Allied Healthcare Products in the first...2009. ,, Sales declines pushed Allied into a lo...was about $745,000, or negative 9 cents per share,...t $208,000, or 3 cents per share. ,, Sales fel...
Breaking Medicine Technology:Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care 2Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care 3SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 2SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 3SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 4SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 5SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 6SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 7SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 8SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 9Recession Continues to Depress Sales at Allied Healthcare Products 2Recession Continues to Depress Sales at Allied Healthcare Products 3Recession Continues to Depress Sales at Allied Healthcare Products 4Recession Continues to Depress Sales at Allied Healthcare Products 5Recession Continues to Depress Sales at Allied Healthcare Products 6Cooper Martin Unveils Innovative Stylish Recovery Clothing for Those with Limited Mobility 48188 1Cooper Martin Unveils Innovative Stylish Recovery Clothing for Those with Limited Mobility 48188 2Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery 4564 1Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery 4564 2Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery 4564 3Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery 4564 4Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery 4564 5Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association 4562 1Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association 4562 2Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association 4562 3
...y 10, 2007 /PRNewswire/ --,Pieris AG, a bio-pharma... class of targeted human protein therapeutics, tod...vel, effective products for,the potential treatmen... Anticalin(R) candidate, the Company reports that ...rget of action via,the lungs. , PRS-060 has been s...
...st for meeting with FDA, SEATTLE, July 11, 2007 /P...TI) announced today that interim results of,its ph...rone is,substituted for doxorubicin in standard CH...ive non-Hodgkin,s lymphoma (NHL), resulted,in esse...r,objective anti-tumor response (complete response...
Other Medicine Technology:Pieris Progresses Proprietary Asthma Program: Validation of,Pulmonary Delivery of Anticalin-Based Protein Product Candidate 2Pixantrone Combination Therapy for First-line Treatment of,Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe,Toxicities Including Heart Damage When Compared to,Doxorubicin-based Therapy 2Pixantrone Combination Therapy for First-line Treatment of,Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe,Toxicities Including Heart Damage When Compared to,Doxorubicin-based Therapy 3Pixantrone Combination Therapy for First-line Treatment of,Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe,Toxicities Including Heart Damage When Compared to,Doxorubicin-based Therapy 4Pixantrone Combination Therapy for First-line Treatment of,Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe,Toxicities Including Heart Damage When Compared to,Doxorubicin-based Therapy 5
(Date:11/8/2009)...RNewswire-USNewswire/ -- Tonight the House of Repr...America Act, landmark health reform legislation th...y, affordable, stable and secure health care cover... the insurance industry,s worst practices, would e... deficit by $104 billion over ten years. Groups re...
(Date:11/8/2009)...en’s Health Network (MHN) urges military vet...y those linked to exposure to chemicals, atomic ag...der cancer is one of those cancers that is two tim...o once smoked or currently smoke cigarettes. , ...er 8, 2009 -- Men’s Health Network (MHN) kic...
(Date:11/8/2009)...work of Hispanic health advocates committed to ach..., WASHINGTON, Nov. 7 "T...ey have heard the voice of America,s families by p... Now the Senate must deliver, without delay, on th...Dr. Jane L. Delgado, President and CEO of the Nati...
(Date:11/8/2009)...RNewswire-USNewswire/ -- The following was release...ue Insurrecta Nex. ,, Mr. Terry and his associ... keep child-killing by abortion out of any health ...s is a great first step to victory -- a touchdown ...ing ahead of us. Our rejoicing must be tempered by...
(Date:11/8/2009)...v. 8 March of Dimes hos...on to recognize prominent individuals who are cele...le models for March of Dimes commitment to improve...mes November Prematurity Awareness Month campaign,... the fight for preemies! ,, (Photo: http://ww...
Breaking Medicine News(10 mins):Health News:Democratic National Committee Chairman Tim Kaine Issues Statement Praising the House of Representative's Historic Vote to Pass Health Insurance Reform 2Health News:Democratic National Committee Chairman Tim Kaine Issues Statement Praising the House of Representative's Historic Vote to Pass Health Insurance Reform 3Health News:Veterans' Day Reminder from Men's Health Network: Pay Attention to Bladder Cancer Symptoms and Risk Factors 2Health News:Veterans' Day Reminder from Men's Health Network: Pay Attention to Bladder Cancer Symptoms and Risk Factors 3Health News:National Alliance for Hispanic Health President and CEO Applauds House Action, Calls on Senate to Pass Health Reform in 2009 2Health News:Hollywood Stars Joined in a Celebration of Babies 2Health News:Hollywood Stars Joined in a Celebration of Babies 3
...nating Extras, Delaying Retirement , , SAN MATEO... Caring.com , approximately forty-five percent ... are providing them with financial assistance, wit...ew research study conducted by Caring.com to measu...
... to cover science-based approaches to sex educatio...o the latest data available, the U.S. Centers for ...or the second straight year in 2007. Although teen...nce in sex education for teens. , , In response, ...
...CandleInTheWindow.org announces a $1,000 scholars...mbol that tells pregnant women in need that the be...y need. , , "We want to get beyond the labels of...em willing to help them during and after their pre...
...rmone levels in the blood as a marker of breast ca... blood tests reflect what is happening in the brea...searchers at Georgetown University Medical Center,...cessarily reflect the levels of these hormones in ...
...nd bars in the United States than in any other cou... than just its inmates---it also takes a toll on t... In the first known study of its kind, University...d depressive symptoms than those without a loved o...
...eagues from King,s College London, has found that ...their family carers in sub-Saharan Africa often do...s disease and its management, which impacts negati...aboration with five palliative care services in So...
Other Medicine News:Health News:After the Crash, Forty-Five Percent of Caring.com Visitors are Providing Financial Support to Aging Parents 2Health News:After the Crash, Forty-Five Percent of Caring.com Visitors are Providing Financial Support to Aging Parents 3Health News:Penn State Conference to Address Rising Teen Pregnancy Rates 2Health News:$1000 Scholarship/Award for Best Poster/Ribbon Design That Encourages Needy Pregnant Women to Ask Bearers for Help 2Health News:Test for hormones in blood not reflective of hormones in breast tissue; breast cancer risk 2Health News:Prison punishes more people than just the inmates 2Health News:Palliative care skills training needed for health-care staff in sub-Saharan Africa 2
... Drawing on over 20 years of CT engineering innova... 16 is at the forefront of the revolution in CT im... data at high speed with superb spatial resolution... clinical experience and close cooperation with le...
... The Mx8000 IDT 16 is Philips premium 16-slice CT ...are performed to automatically delivering high qua...ates a new direction in a platform that has been t...o comprehensive organ assessment literally within ...
... The TLIF Instruments are designed to facilitate d... non-structural bone graft during interbody fusion...ow easy use during TLIF, for which they were prima...effectively in PLIF and ALIF. Disc rongeurs: used ...
Pathfinder
Medicine Products: